印度

Transforming a small pathology lab into a $1bn business

Ameera Shah, managing director of India’s Metropolis Healthcare, returned to her Mumbai home in mid-March, after giving birth to her first child. Her plan was to spend a month “without worrying about Metropolis,” the nationwide chain of diagnostics laboratories she had built over the previous two decades.

But coronavirus cases had begun emerging in India, where authorities had done little to prepare for the pandemic. Ms Shah was soon ensnared in calls with government officials about testing policies.

On March 23, New Delhi permitted six private pathology labs — including Metropolis — to start testing for the pathogen. A day later, Prime Minister Narendra Modi abruptly imposed a nationwide coronavirus lockdown. The 40-year-old entrepreneur — who by then had retreated with her husband, parents and baby to a house in the countryside — found herself at the centre of a maelstrom, trying to help her company ramp up its coronavirus testing capacity amid the severe disruption of the lockdown.

您已閱讀14%(997字),剩餘86%(6225字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×